Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Plans Three NME Filings In 2005, Including First Oral VEGF Inhibitor

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novartis plans three NME filings in 2005, including first oral VEGF agent, firm says during Jan. 20 R&D day. PTK787 has blockbuster potential in colorectal cancer, Novartis says. Nine more NME filings are scheduled for next two years
Advertisement

Related Content

Novartis Rasilez NDA in early ‘06
Novartis Exjade Review Complicated By Use Of SQUID To Measure Iron Levels
Novartis telbivudine Phase III HBV data
Novartis submits Exjade iron chelator
Novartis/Schering Vatalanib NDA Delayed Until 2007; Misses Primary Endpoint
Diabetes Drug Advances Are Highlight Of NMEs Pending In 2005
Diabetes Drug Advances Are Highlight Of NMEs Pending In 2005

Topics

Advertisement
UsernamePublicRestriction

Register

PS002789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel